Literature DB >> 10981080

Mechanism of action of angiotensin-receptor blocking agents.

H M Siragy1, M Bedigian.   

Abstract

Angiotensin II is the most active hormone of the renin-angiotensin system. In humans, two angiotensin receptors have been identified: AT(1) and AT(2). In adults, most of the effects of angiotensin II are mediated by the AT(1) receptor; the function of the AT(2) receptor is not yet well established. Angiotensin II has both systemic and local paracrine effects. Increased activity of angiotensin II and stimulation of the AT(1) receptor have been linked to the development of several cardiovascular and renal diseases, including hypertension, heart failure, left ventricular hypertrophy, and diabetic nephropathy. Over the past two decades, angiotensin-converting enzymes have been used to manage these diseases. However, the side effects and less-than- maximum therapeutic effects of angiotensin-converting enzyme inhibitors, particularly in the decrease of mortality associated with congestive heart failure, have led to the development of AT(1)-receptor blockers.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10981080     DOI: 10.1007/s11906-999-0036-3

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  57 in total

1.  Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors.

Authors:  Y H Liu; X P Yang; V G Sharov; O Nass; H N Sabbah; E Peterson; O A Carretero
Journal:  J Clin Invest       Date:  1997-04-15       Impact factor: 14.808

2.  Angiotensin II blockade decreases TGF-beta1 and matrix proteins in cyclosporine nephropathy.

Authors:  F S Shihab; W M Bennett; A M Tanner; T F Andoh
Journal:  Kidney Int       Date:  1997-09       Impact factor: 10.612

3.  A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension.

Authors:  A Mimran; L Ruilope; L Kerwin; M Nys; D Owens; K Kassler-Taub; M Osbakken
Journal:  J Hum Hypertens       Date:  1998-03       Impact factor: 3.012

4.  Essential hypertension: renin and aldosterone, heart attack and stroke.

Authors:  H R Brunner; J H Laragh; L Baer; M A Newton; F T Goodwin; L R Krakoff; R H Bard; F R Bühler
Journal:  N Engl J Med       Date:  1972-03-02       Impact factor: 91.245

5.  Antihypertensive therapy with MK 421: angiotensin II--renin relationships to evaluate efficacy of converting enzyme blockade.

Authors:  J Biollaz; H R Brunner; I Gavras; B Waeber; H Gavras
Journal:  J Cardiovasc Pharmacol       Date:  1982 Nov-Dec       Impact factor: 3.105

6.  Tissue-specific expression of human angiotensin II AT1 and AT2 receptors and cellular localization of subtype mRNAs in adult human renal cortex using in situ hybridization.

Authors:  H Matsubara; T Sugaya; S Murasawa; Y Nozawa; Y Mori; H Masaki; K Maruyama; Y Tsutumi; Y Shibasaki; Y Moriguchi; Y Tanaka; T Iwasaka; M Inada
Journal:  Nephron       Date:  1998-09       Impact factor: 2.847

Review 7.  Rationale and pharmacology of angiotensin II receptor antagonists: current status and future issues.

Authors:  C I Johnston; M Naitoh; L M Burrell
Journal:  J Hypertens Suppl       Date:  1997-12

8.  Molecular characterization and chromosome localization of a human angiotensin II AT2 receptor gene highly expressed in fetal tissues.

Authors:  D Lazard; M M Briend-Sutren; P Villageois; M G Mattei; A D Strosberg; C Nahmias
Journal:  Receptors Channels       Date:  1994

9.  Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction.

Authors:  Y Nio; H Matsubara; S Murasawa; M Kanasaki; M Inada
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

10.  Characterization of angiotensin II receptor type 2 during differentiation and apoptosis of rat ovarian cultured granulosa cells.

Authors:  M Tanaka; J Ohnishi; Y Ozawa; M Sugimoto; S Usuki; M Naruse; K Murakami; H Miyazaki
Journal:  Biochem Biophys Res Commun       Date:  1995-02-15       Impact factor: 3.575

View more
  6 in total

Review 1.  PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ.

Authors:  Lu Han; Wen-Jun Shen; Stefanie Bittner; Fredric B Kraemer; Salman Azhar
Journal:  Future Cardiol       Date:  2017-06-05

2.  Effect of unilateral ureteral obstruction and anti-angiotensin II treatment on renal tubule and interstitial cell apoptosis in rats.

Authors:  Nikola Radović; Snjezan Cuzić; Mladen Knotek
Journal:  Croat Med J       Date:  2008-10       Impact factor: 1.351

3.  Intratubular Renin-Angiotensin System in Hypertension.

Authors:  Yuki Suzaki; Minolfa C Prieto-Carrasquero; Hiroyuki Kobori
Journal:  Curr Hypertens Rev       Date:  2006

4.  Critical appraisal and pooled analysis of telmisartan alone or in combination with hydrochlorothiazide for achieving blood pressure goals.

Authors:  Satoshi Morimoto; Nobuyuki Takahashi; Tatsuyori Morita; Kazunori Someya; Nagaoki Toyoda; Toshiji Iwasaka
Journal:  Integr Blood Press Control       Date:  2010-06-03

5.  Effects of hydroxyethyl starch 130/0.4 on the kidney tissue of rats with ureteral obstruction.

Authors:  Işın Güneş; Nuran Süngü; Aydan Kılıçarslan; Volkan Şıvgın; Metin Alkan; Ayşegül Küçük; Hakan Boyunağa; Yusuf Ünal; Mustafa Arslan
Journal:  Drug Des Devel Ther       Date:  2018-09-20       Impact factor: 4.162

6.  Selective inhibition of histone deacetylase 8 improves vascular hypertrophy, relaxation, and inflammation in angiotensin II hypertensive mice.

Authors:  Hae Jin Kee; Yuhee Ryu; Young Mi Seok; Sin Young Choi; Simei Sun; Gwi Ran Kim; Myung Ho Jeong
Journal:  Clin Hypertens       Date:  2019-06-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.